Cancer drug developer Sareum Holdings Plc (LON:SAR) now has patent protection in China and Hong Kong for its Aurora+FLT3 inhibitor programme after receiving approval from the relevant authorities, it revealed.
The firm received similar patents the USA and Europe in September last year.
Other major territories, including Japan, are expected to follow in due course.
Chief scientific officer Dr John Reader said: " These notifications of patent grants for Sareum in China and Hong Kong demonstrate the strength of intellectual property protecting our Aurora+FLT3 programme, and reinforces the patent position for HMUBEC, our development partner in China."
Sareum's Aurora+FLT3 inhibitor programme targets acute myeloid leukaemia (AML) and other leukaemias and lymphomas.
"In disease models of AML, the preclinical development candidate molecule demonstrates greater than 98% tumour inhibition. Preclinical development studies to obtain approval for human clinical trials are being undertaken in collaboration with, and funded by, Hebei Medical University Biomedical Engineering Center (HMUBEC) in China," the firm said in today's statement.
MF